Treprostinil

Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.

Product Specifications

CAS Number

[81846-19-7]

Product Name Alternative

UT-15

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Treprostinil.html

Purity

99.98

Solubility

DMSO : ≥ 125 mg/mL

Smiles

OC(COC1=CC=CC2=C1C[C@](C[C@@H](O)[C@@H]3CC[C@@H](O)CCCCC)([H])[C@]3([H])C2)=O

Molecular Formula

C23H34O5

Molecular Weight

390.51

Precautions

H302, H312, H332

References & Citations

[1]Whittle BJ, et al. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012 Jul 1;84 (1) :68-75.|[2]Ferrantino M, et al. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2011 Nov;12 (16) :2583-93.|[3]Ghonem N, et al. Treprostinil, a prostacyclin analog, ameliorates ischemia-reperfusion injury in rat orthotopic liver transplantation. Am J Transplant. 2011 Nov;11 (11) :2508-16.|[4]Smadja DM, et al. Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells. Thromb Haemost. 2015 Oct;114 (4) :735-47.|[5]Kazemi Z, et al. Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation. Mol Pharmacol. 2016 Jun;89 (6) :630-44.|[6]Nikam VS, et al. Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J. 2010 Dec;36 (6) :1302-14.